Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Havrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 69-year-old female patient who received HAV (Havrix) for prophylaxis. Previously administered products included Havrix (received 1st dose of Havrix vaccine in 16-APR-2008). On 04-JUN-2024, the patient received the 2nd dose of Havrix. On 04-JUN-2024, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too long (Verbatim: Havrix late second dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-MAR-2025 The pharmacist asked if she could administer a third dose of Havrix to a patient due to a wide range of time between the first two doses. First dose on 16 April 2008 and the second in 4 June 2024, which led to drug dose administration interval too long.